Skopos Labs, Inc. Apellis Pharmaceuticals, Inc. Transaction History
Skopos Labs, Inc.
- $453 Million
- Q1 2025
A detailed history of Skopos Labs, Inc. transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Skopos Labs, Inc. holds 212 shares of APLS stock, worth $3,989. This represents 0.0% of its overall portfolio holdings.
Number of Shares
212
Previous 241
12.03%
Holding current value
$3,989
Previous $7,000
42.86%
% of portfolio
0.0%
Previous 0.0%
Shares
3 transactions
Others Institutions Holding APLS
# of Institutions
295Shares Held
124MCall Options Held
921KPut Options Held
761K-
Wellington Management Group LLP Boston, MA12.3MShares$232 Million0.05% of portfolio
-
Avoro Capital Advisors LLC New York, NY12.2MShares$230 Million4.32% of portfolio
-
Eco R1 Capital, LLC San Francisco, CA11.9MShares$224 Million20.45% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.1MShares$191 Million0.0% of portfolio
-
Morgan Stanley New York, NY9.63MShares$181 Million0.02% of portfolio
About Apellis Pharmaceuticals, Inc.
- Ticker APLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 109,865,000
- Market Cap $2.07B
- Description
- Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...